Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2012 7
2013 9
2014 19
2015 41
2016 44
2017 33
2018 32
2019 6
2020 9
2021 13
2022 5
2023 4
2024 4
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

227 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group. RECOVERY Collaborative Group. Lancet. 2021 May 1;397(10285):1637-1645. doi: 10.1016/S0140-6736(21)00676-0. Lancet. 2021. PMID: 33933206 Free PMC article. Clinical Trial.
Overall, 621 (31%) of the 2022 patients allocated tocilizumab and 729 (35%) of the 2094 patients allocated to usual care died within 28 days (rate ratio 0.85; 95% CI 0.76-0.94; p=0.0028). Consistent results were seen in all prespecified subgroups of patients, including tho …
Overall, 621 (31%) of the 2022 patients allocated tocilizumab and 729 (35%) of the 2094 patients allocated to usual care died within 28 days …
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.
RECOVERY Collaborative Group. RECOVERY Collaborative Group. Lancet. 2022 Jul 30;400(10349):359-368. doi: 10.1016/S0140-6736(22)01109-6. Lancet. 2022. PMID: 35908569 Free PMC article. Clinical Trial.
Overall, 514 (12%) of 4148 patients allocated to baricitinib versus 546 (14%) of 4008 patients allocated to usual care died within 28 days (age-adjusted rate ratio 0.87; 95% CI 0.77-0.99; p=0.028). This 13% proportional reduction in mortality was somewhat smaller than that …
Overall, 514 (12%) of 4148 patients allocated to baricitinib versus 546 (14%) of 4008 patients allocated to usual care died within 28 days ( …
Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group. Electronic address: recoverytrial@ndph.ox.ac.uk; RECOVERY Collaborative Group. RECOVERY Collaborative Group. Electronic address: recoverytrial@ndph.ox.ac.uk, et al. Lancet. 2023 May 6;401(10387):1499-1507. doi: 10.1016/S0140-6736(23)00510-X. Epub 2023 Apr 13. Lancet. 2023. PMID: 37060915 Free PMC article. Clinical Trial.
Overall, 123 (19%) of 659 patients allocated to higher dose corticosteroids versus 75 (12%) of 613 patients allocated to usual care died within 28 days (rate ratio 1.59 [95% CI 1.20-2.10]; p=0.0012). There was also an excess of pneumonia reported to be due to non-COVID inf …
Overall, 123 (19%) of 659 patients allocated to higher dose corticosteroids versus 75 (12%) of 613 patients allocated to usual care died wit …
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial.
RECOVERY Collaborative Group. RECOVERY Collaborative Group. Lancet. 2021 May 29;397(10289):2049-2059. doi: 10.1016/S0140-6736(21)00897-7. Epub 2021 May 14. Lancet. 2021. PMID: 34000257 Free PMC article. Clinical Trial.
There was no significant difference in 28-day mortality between the two groups: 1399 (24%) of 5795 patients in the convalescent plasma group and 1408 (24%) of 5763 patients in the usual care group died within 28 days (rate ratio 1.00, 95% CI 0.93-1.07; p=0.95). The 28-day …
There was no significant difference in 28-day mortality between the two groups: 1399 (24%) of 5795 patients in the convalescent plasma group …
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group. RECOVERY Collaborative Group. Lancet Diabetes Endocrinol. 2023 Dec;11(12):905-914. doi: 10.1016/S2213-8587(23)00253-X. Epub 2023 Oct 18. Lancet Diabetes Endocrinol. 2023. PMID: 37865101 Free PMC article. Clinical Trial.
Overall, 289 (14%) of 2113 patients allocated to empagliflozin and 307 (14%) of 2158 patients allocated to usual care died within 28 days (rate ratio 0.96 [95% CI 0.82-1.13]; p=0.64). There was no evidence of significant differences in duration of hospitalisation (median 8 …
Overall, 289 (14%) of 2113 patients allocated to empagliflozin and 307 (14%) of 2158 patients allocated to usual care died within 28 days (r …
Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group. RECOVERY Collaborative Group. Lancet. 2022 Jan 8;399(10320):143-151. doi: 10.1016/S0140-6736(21)01825-0. Epub 2021 Nov 17. Lancet. 2022. PMID: 34800427 Free PMC article. Clinical Trial.
Overall, 1222 (17%) of 7351 patients allocated to aspirin and 1299 (17%) of 7541 patients allocated to usual care died within 28 days (rate ratio 0.96, 95% CI 0.89-1.04; p=0.35). Consistent results were seen in all prespecified subgroups of patients. Patients allocated to …
Overall, 1222 (17%) of 7351 patients allocated to aspirin and 1299 (17%) of 7541 patients allocated to usual care died within 28 days (rate …
Laser cooling of antihydrogen atoms.
Baker CJ, Bertsche W, Capra A, Carruth C, Cesar CL, Charlton M, Christensen A, Collister R, Mathad AC, Eriksson S, Evans A, Evetts N, Fajans J, Friesen T, Fujiwara MC, Gill DR, Grandemange P, Granum P, Hangst JS, Hardy WN, Hayden ME, Hodgkinson D, Hunter E, Isaac CA, Johnson MA, Jones JM, Jones SA, Jonsell S, Khramov A, Knapp P, Kurchaninov L, Madsen N, Maxwell D, McKenna JTK, Menary S, Michan JM, Momose T, Mullan PS, Munich JJ, Olchanski K, Olin A, Peszka J, Powell A, Pusa P, Rasmussen CØ, Robicheaux F, Sacramento RL, Sameed M, Sarid E, Silveira DM, Starko DM, So C, Stutter G, Tharp TD, Thibeault A, Thompson RI, van der Werf DP, Wurtele JS. Baker CJ, et al. Nature. 2021 Apr;592(7852):35-42. doi: 10.1038/s41586-021-03289-6. Epub 2021 Mar 31. Nature. 2021. PMID: 33790445 Free PMC article.
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group. RECOVERY Collaborative Group. Lancet. 2022 Feb 12;399(10325):665-676. doi: 10.1016/S0140-6736(22)00163-5. Lancet. 2022. PMID: 35151397 Free PMC article. Clinical Trial.
In the primary efficacy population of seronegative patients, 396 (24%) of 1633 patients allocated to casirivimab and imdevimab versus 452 (30%) of 1520 patients allocated to usual care died within 28 days (rate ratio [RR] 0.79, 95% CI 0.69-0.91; p=0.0009). In an analysis o …
In the primary efficacy population of seronegative patients, 396 (24%) of 1633 patients allocated to casirivimab and imdevimab versus 452 (3 …
Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group. RECOVERY Collaborative Group. EClinicalMedicine. 2025 Feb 12;81:103080. doi: 10.1016/j.eclinm.2025.103080. eCollection 2025 Mar. EClinicalMedicine. 2025. PMID: 40036152 Free PMC article.
Overall, 86 (35%) of 246 patients allocated to higher dose corticosteroids vs. 86 (37%) of 231 patients allocated to usual care died within 28 days (rate ratio [RR] 0.87; 95% CI 0.64-1.18; p = 0.37). There was no significant difference in the proportion of patients dischar …
Overall, 86 (35%) of 246 patients allocated to higher dose corticosteroids vs. 86 (37%) of 231 patients allocated to usual care died within …
Response to treatment in NMOSD: the Australasian experience.
Clarke L, Bukhari W, O'Gorman CM, Khalilidehkordi E, Arnett S, Woodhall M, Prain KM, Parratt JDE, Barnett MH, Marriott MP, McCombe PA, Sutton I, Boggild M, Brownlee W, Carroll WM, Hodgkinson S, Macdonell RAL, Mason DF, Pereira J, Slee M, Das C, Henderson APD, Kermode AG, Lechner-Scott J; ANZ NMO Collaboration; Waters P, Sun J, Broadley SA. Clarke L, et al. Mult Scler Relat Disord. 2022 Feb;58:103408. doi: 10.1016/j.msard.2021.103408. Epub 2021 Nov 21. Mult Scler Relat Disord. 2022. PMID: 35216788
In a time to first relapse analysis rituximab showed a risk ratio of 0.23 (95% CI 0.08 - 0.65) when compared with no treatment and there was a non-significant reduction in ARR of 35% compared to pre-treatment. beta-interferon (p = 0.0002) and cyclophosphamide (p = 0 …
In a time to first relapse analysis rituximab showed a risk ratio of 0.23 (95% CI 0.08 - 0.65) when compared with no treatment and there was …
227 results